| pubmed-article:20098430 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:20098430 | lifeskim:mentions | umls-concept:C1801960 | lld:lifeskim |
| pubmed-article:20098430 | lifeskim:mentions | umls-concept:C0003009 | lld:lifeskim |
| pubmed-article:20098430 | lifeskim:mentions | umls-concept:C0120465 | lld:lifeskim |
| pubmed-article:20098430 | lifeskim:mentions | umls-concept:C0005823 | lld:lifeskim |
| pubmed-article:20098430 | lifeskim:mentions | umls-concept:C1280500 | lld:lifeskim |
| pubmed-article:20098430 | lifeskim:mentions | umls-concept:C1332110 | lld:lifeskim |
| pubmed-article:20098430 | lifeskim:mentions | umls-concept:C1412517 | lld:lifeskim |
| pubmed-article:20098430 | lifeskim:mentions | umls-concept:C1423613 | lld:lifeskim |
| pubmed-article:20098430 | lifeskim:mentions | umls-concept:C0086597 | lld:lifeskim |
| pubmed-article:20098430 | lifeskim:mentions | umls-concept:C1720675 | lld:lifeskim |
| pubmed-article:20098430 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:20098430 | pubmed:dateCreated | 2010-2-5 | lld:pubmed |
| pubmed-article:20098430 | pubmed:abstractText | Hypertension is one of the most frequent pathologies in the industrialized world. Although recognized to be dependent on a combination of genetic and environmental factors, its molecular basis remains elusive. Increased activity of the monomeric G protein RhoA in arteries is a common feature of hypertension. However, how RhoA is activated and whether it has a causative role in hypertension remains unclear. Here we provide evidence that Arhgef1 is the RhoA guanine exchange factor specifically responsible for angiotensin II-induced activation of RhoA signaling in arterial smooth muscle cells. We found that angiotensin II activates Arhgef1 through a previously undescribed mechanism in which Jak2 phosphorylates Tyr738 of Arhgef1. Arhgef1 inactivation in smooth muscle induced resistance to angiotensin II-dependent hypertension in mice, but did not affect normal blood pressure regulation. Our results show that control of RhoA signaling through Arhgef1 is central to the development of angiotensin II-dependent hypertension and identify Arhgef1 as a potential target for the treatment of hypertension. | lld:pubmed |
| pubmed-article:20098430 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20098430 | pubmed:language | eng | lld:pubmed |
| pubmed-article:20098430 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20098430 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:20098430 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20098430 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20098430 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20098430 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20098430 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20098430 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20098430 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:20098430 | pubmed:month | Feb | lld:pubmed |
| pubmed-article:20098430 | pubmed:issn | 1546-170X | lld:pubmed |
| pubmed-article:20098430 | pubmed:author | pubmed-author:LoufraniLaure... | lld:pubmed |
| pubmed-article:20098430 | pubmed:author | pubmed-author:HenrionDaniel... | lld:pubmed |
| pubmed-article:20098430 | pubmed:author | pubmed-author:BrilAntoineA | lld:pubmed |
| pubmed-article:20098430 | pubmed:author | pubmed-author:TorresRaul... | lld:pubmed |
| pubmed-article:20098430 | pubmed:author | pubmed-author:ScalbertEliza... | lld:pubmed |
| pubmed-article:20098430 | pubmed:author | pubmed-author:Rolli-Derkind... | lld:pubmed |
| pubmed-article:20098430 | pubmed:author | pubmed-author:ToumaniantzGi... | lld:pubmed |
| pubmed-article:20098430 | pubmed:author | pubmed-author:PacaudPierreP | lld:pubmed |
| pubmed-article:20098430 | pubmed:author | pubmed-author:LoirandGervai... | lld:pubmed |
| pubmed-article:20098430 | pubmed:author | pubmed-author:GuilluyChrist... | lld:pubmed |
| pubmed-article:20098430 | pubmed:author | pubmed-author:RetailleauKev... | lld:pubmed |
| pubmed-article:20098430 | pubmed:author | pubmed-author:BrégeonJérémy... | lld:pubmed |
| pubmed-article:20098430 | pubmed:author | pubmed-author:OffermannsSte... | lld:pubmed |
| pubmed-article:20098430 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:20098430 | pubmed:volume | 16 | lld:pubmed |
| pubmed-article:20098430 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:20098430 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:20098430 | pubmed:pagination | 183-90 | lld:pubmed |
| pubmed-article:20098430 | pubmed:meshHeading | pubmed-meshheading:20098430... | lld:pubmed |
| pubmed-article:20098430 | pubmed:meshHeading | pubmed-meshheading:20098430... | lld:pubmed |
| pubmed-article:20098430 | pubmed:meshHeading | pubmed-meshheading:20098430... | lld:pubmed |
| pubmed-article:20098430 | pubmed:meshHeading | pubmed-meshheading:20098430... | lld:pubmed |
| pubmed-article:20098430 | pubmed:meshHeading | pubmed-meshheading:20098430... | lld:pubmed |
| pubmed-article:20098430 | pubmed:meshHeading | pubmed-meshheading:20098430... | lld:pubmed |
| pubmed-article:20098430 | pubmed:meshHeading | pubmed-meshheading:20098430... | lld:pubmed |
| pubmed-article:20098430 | pubmed:meshHeading | pubmed-meshheading:20098430... | lld:pubmed |
| pubmed-article:20098430 | pubmed:meshHeading | pubmed-meshheading:20098430... | lld:pubmed |
| pubmed-article:20098430 | pubmed:meshHeading | pubmed-meshheading:20098430... | lld:pubmed |
| pubmed-article:20098430 | pubmed:meshHeading | pubmed-meshheading:20098430... | lld:pubmed |
| pubmed-article:20098430 | pubmed:meshHeading | pubmed-meshheading:20098430... | lld:pubmed |
| pubmed-article:20098430 | pubmed:meshHeading | pubmed-meshheading:20098430... | lld:pubmed |
| pubmed-article:20098430 | pubmed:year | 2010 | lld:pubmed |
| pubmed-article:20098430 | pubmed:articleTitle | The Rho exchange factor Arhgef1 mediates the effects of angiotensin II on vascular tone and blood pressure. | lld:pubmed |
| pubmed-article:20098430 | pubmed:affiliation | Inserm, U915, Nantes, France. | lld:pubmed |
| pubmed-article:20098430 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:20098430 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| entrez-gene:16801 | entrezgene:pubmed | pubmed-article:20098430 | lld:entrezgene |
| http://linkedlifedata.com/r... | entrezgene:pubmed | pubmed-article:20098430 | lld:entrezgene |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:20098430 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:20098430 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:20098430 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:20098430 | lld:pubmed |
